跳至主要内容
临床试验/EUCTR2011-003594-28-DE
EUCTR2011-003594-28-DE进行中(未招募)1 期

A Comparative Observational Prospective Randomized Open-Label Study on Efficacy of BioSeed®-C and chondrotissue® Treatment of Local Femoral Cartilage Defects in the Knee. - Comparison of BioSeed®-C treatment with advanced microfracture treatment

BioTissue Technologies GmbH0 个研究点开始时间: 2011年11月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Local femoral defect at the knee joint (Outerbridge class III or IV)
  • Defects at the lateral and medial chondyle
  • Cartilage defect size: (after defect cleaning)
  • Patients male and female between 18 and 50 years of age at the time of surgery
  • Patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical evaluations/visits
  • Patients who have signed the Ethics Committee-approved Informed Consent Form prior to surgery
  • Indications for microfracture or ACT respectively
  • focal and contained lesions
  • full-thickness loss of articular cartilage in weight-bearing areas
  • unstable cartilage covering the underlying intact subchondral bone
  • degenerative changes in a knee that is normally aligned
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Known allergic reactions or hypersensitivity to bovine proteins, PGA, fibrinogen, thrombin, heparin or hyaluronan
  • Defect of the femoropatellar joint
  • Varus and valgus (more than 5°) (30 cm one leg standing apical X-ray)
  • General osteoarthritis (two or more compartments)
  • Rheumatoid arthritis or Bechterew’s disease
  • Joint stiffness (flexion less than 90°)
  • Obesity > 32 BMI
  • Meniscus lesions with more than 1/3 partial resection
  • History with previous cartilage surgery (osteochondral transplantation (OCT), autologous chondrocyte transplantation (ACT))
  • History with previous microfracture in the symptomatic defect less than 6 months
  • History with previous knee surgery (anterior crucial ligament, meniscus refixation, osteotomy) less than 6 months
  • Osteochondral defects
  • Planned pregnancy, pregnancy and breastfeeding
  • Autoimmune-diseases

研究者

发起方
BioTissue Technologies GmbH

相似试验